State of Alaska Department of Revenue Sells 20,525 Shares of Hologic, Inc. (NASDAQ:HOLX)

State of Alaska Department of Revenue lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 168,704 shares of the medical equipment provider’s stock after selling 20,525 shares during the period. State of Alaska Department of Revenue owned approximately 0.07% of Hologic worth $12,161,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Prentiss Smith & Co. Inc. raised its position in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares during the period. Covestor Ltd raised its position in shares of Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the period. First Horizon Advisors Inc. raised its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. Brooklyn Investment Group raised its position in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares during the period. Finally, Empirical Finance LLC raised its position in shares of Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the period. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HOLX. Morgan Stanley dropped their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday. Royal Bank of Canada dropped their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $80.00 to $75.00 in a research report on Thursday. Finally, BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Nine investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.77.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.88% of the stock is currently owned by corporate insiders.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $65.45 on Friday. The stock has a 50 day moving average of $72.63 and a 200-day moving average of $77.86. The company has a market capitalization of $14.77 billion, a P/E ratio of 19.65, a P/E/G ratio of 2.35 and a beta of 0.97. Hologic, Inc. has a 12 month low of $64.87 and a 12 month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.